267 related articles for article (PubMed ID: 36571328)
1. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
[TBL] [Abstract][Full Text] [Related]
2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
3. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
4. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
6. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
[TBL] [Abstract][Full Text] [Related]
7. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
8. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
[TBL] [Abstract][Full Text] [Related]
9. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
10. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
11. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
12. The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients.
Bostancı C; Demir DÖ
Actas Urol Esp (Engl Ed); 2024 Apr; 48(3):238-245. PubMed ID: 37838326
[TBL] [Abstract][Full Text] [Related]
13. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
[TBL] [Abstract][Full Text] [Related]
14. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
[TBL] [Abstract][Full Text] [Related]
15. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
[TBL] [Abstract][Full Text] [Related]
16. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
17. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
18.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
19. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
20. Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?
Anastay V; Gondran-Tellier B; McManus R; Delonca R; Akiki A; Gaillet S; Delaporte V; Andre M; Daniel L; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
Abdom Radiol (NY); 2020 Dec; 45(12):4160-4165. PubMed ID: 32902661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
